- Athenex (NASDAQ:ATNX) shares dropped over 41% during Wednesday's extended trading after the biopharmaceutical company proposed an underwritten public offering of common stocks and warrants.
- Terms of the offering are yet to be determined.
- The offering will consist of shares of ATNX common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of common stock.